Inovio Pharmaceuticals has closed an agreement providing ApolloBio with exclusive rights to develop, manufacture and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat precancers caused by human papillomavirus (HPV), within mainland China, Hong Kong, Macao, and Taiwan. ApolloBio will pay Inovio $23 million upfront as well as potential future payments as much as $20 million upon meeting certain milestones. Inovio is also entitled to receive royalties on sales. This co...